Scorpius Holdings (Scorpius Holdings) Debt-to-Equity : 0.45 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Scorpius Holdings Debt-to-Equity?

Scorpius Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.43 Mil. Scorpius Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $12.61 Mil. Scorpius Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $31.40 Mil. Scorpius Holdings's debt to equity for the quarter that ended in Dec. 2023 was 0.45.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Scorpius Holdings's Debt-to-Equity or its related term are showing as below:

SCPX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.14 Max: 1.67
Current: 0.45

During the past 13 years, the highest Debt-to-Equity Ratio of Scorpius Holdings was 1.67. The lowest was 0.02. And the median was 0.14.

SCPX's Debt-to-Equity is ranked worse than
73.31% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs SCPX: 0.45

Scorpius Holdings Debt-to-Equity Historical Data

The historical data trend for Scorpius Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scorpius Holdings Debt-to-Equity Chart

Scorpius Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.14

0.02

0.13

0.45

Scorpius Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.13	0.15	0.23	0.37	0.45

Competitive Comparison of Scorpius Holdings's Debt-to-Equity

For the Biotechnology subindustry, Scorpius Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scorpius Holdings's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scorpius Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Scorpius Holdings's Debt-to-Equity falls into.

Scorpius Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Scorpius Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.429	+	12.613)	/	31.397
	=	0.45

Scorpius Holdings's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.429	+	12.613)	/	31.397
	=	0.45

Scorpius Holdings (AMEX:SCPX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Scorpius Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Scorpius Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Scorpius Holdings (Scorpius Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scorpius Holdings Inc (AMEX:SCPX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

1HB:Germany

Address

627 Davis Drive, Suite 300, Morrisville, NC, USA, 27560

Website

https://www.nighthawkbio.com

NightHawk Biosciences Inc is a commercial-stage company with a fully integrated ecosystem to accelerate the discovery and development of novel therapies that arm the immune system. By leveraging its proprietary platforms, the company is advancing its first-in-class product portfolio with a focus on cancer and inflammatory and infectious diseases. Its current pipeline has categories: Oncology, immunology and molecular biology.

Executives

Prendergast John K A	director	ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Jeffrey Alan Wolf	director, officer: Chief Executive Officer	3985 RESEARCH PARK DRIVE, ANN ARBOR MI 48108
Smith Edward B Iii	director	C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036
William L. Ostrander	officer: CFO/Corp Secy	801 CAPITOLA DRIVE, SUITE 12, DURHAM NC 27713
John J Monahan	director
Robert James Jakobs	officer: VP Finance/Controller/Secty	PO BOX 14487, DURHAM NC 27709
Jeff Tobin Hutchins	officer: Chief Scientific Officer	15823 S. 4210 RD., CLAREMORE OK 74017
Ann A Rosar	officer: VP of Finance and Controller	C/O 801 CAPITOLA DRIVE, DURHAM NC 27713
Michael Kharitonov	director	100 EUROPA DRIVE, CHAPEL HILL NC 27517
Timothy J Creech	officer: Chief Financial Officer	C/O TRIMERIS, INC., 3518 WESTGATE DR. SUITE 300, DURHAM NC 27707
Stephen J. Dipalma	officer: Interim CFO	C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Aristar Heat, Llc	10 percent owner	1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Aristar Capital Management, Llc	10 percent owner	1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Aristar Capital Management Gp, Llc	10 percent owner	1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Taylor Schreiber	officer: Vice President of Research	100 EUROPA DRIVE, CHAPEL HILL NC 27517